CLGN Stock, CollPlant Holdings Ltd. Information

CollPlant is a regenerative medicine company leveraging its proprietary, plant based recombinant human collagen rhCollagen technology for the development and commercialization of tissue repair products, initially for D Bio printing of tissue and organs, for orthobiologics and advanced wound care markets. The Company s cutting edge technology is designed to generate and process proprietary rhCollagen, among other patent protected recombinant proteins. Given that CollPlant s rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company s broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix R STR Soft Tissue Repair Matrix , for the treatment of tendinopathy and Vergenix R FG Flowable Gel wound filler, for treatment of acute and chronic wounds. CollPlant s business strategy includes proprietary development and manufacture of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacture and marketing of additional products.